Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 1, 2007, Pages 1-7

  Shigeto, Makoto ^a   Katsura, Masashi ^a   Matsuda, Masafumi ^a   Ohkuma, Seitaro ^a   Kaku, Kohei ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DANTROLENE; DIAZOXIDE; GLIBENCLAMIDE; INSULIN; MITIGLINIDE; NATEGLINIDE; TOLBUTAMIDE; VERAPAMIL;

ANIMAL CELL; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DOSE RESPONSE; ENDOPLASMIC RETICULUM; INSULIN RELEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CALCIUM; CELL LINE; CYCLOHEXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPLASMIC RETICULUM; HYPOGLYCEMIC AGENTS; INDOLES; INSULIN; INSULIN-SECRETING CELLS; MICE; PHENYLALANINE; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SULFONYLUREA COMPOUNDS;

EID: 34250783198     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.120592     Document Type: Article

References (30)

1. Akiyoshi M, Kakei M, Nakazaki M, and Tanaka H (1995) A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic beta-cells. Am J Physiol 268:E185-E193.
2. Brillantes AB, Ondrias K, Scott A, Kobrinsky E, Ondriasova E, Moschella MC, Jayaraman T, Landers M, Ehrlich BE, and Marks AR (1994) Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. Cell 77:513-523.
3. DECODE study group (2001) Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397-405.
4. Doyle ME and Egan JM (2003) Pharmacological agents that directly modulate insulin secretion. Pharmacol Rev 55:105-131.
5. Grimberg A, Ferry RJ Jr., Kelly A, Koo-McCoy S, Polonsky K, Glaser B, Permutt MA, Aguilar-Bryan L, Stafford D, Thornton PS, et al. (2001) Dysregulation of insulin secretion in children with congenital hyperinsulinism due to sulfonylurea receptor mutations. Diabetes 50:322-328.
6. Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, and Dunning BE (2001) Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 24:983-988.
7. Hu S, Boettcher BR, and Dunning BE (2003) The mechanisms underlying the unique pharmacodynamics of nateglinide. Diabetologia 46 (Suppl 1):M37-M43.
8. Hu S, Wang S, and Dunning BE (2001) Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide. Int J Exp Diabetes Res 2:63-72.
9. Ikenoue T, Akiyoshi M, Fujitani S, Okazaki K, Kondo N, and Maki T (1997) Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D- phenylalanine (A-4166). Br J Pharmacol 120:137-145.
10. Ishihara H, Asano T, Tsukuda K, Katagiri H, Inukai K, Anai M, Kikuchi M, Yazaki Y, Miyazaki JI, and Oka Y (1993) Pancreatic beta cell line MIN6 exhibits characteristics of glucose metabolism and glucose-stimulated insulin secretion similar to those of normal islets. Diabetologia 36:1139-1145.
11. Islam MS (2002) The ryanodine receptor calcium channel of beta-cells: molecular regulation and physiological significance. Diabetes 51:1299-1309.
12. Johnson JD, Kuang S, Misler S, and Polonsky KS (2004) Ryanodine receptors in human pancreatic beta cells: localization and effects on insulin secretion. FASEB J 18:878-880.
13. Katsura M, Shuto K, Mohri Y, Tsujimura A, Shibata D, Tachi M, and Ohkuma S (2004) Continuous exposure to nitric oxide enhances diazepam binding inhibitor mRNA expression in mouse cerebral cortical neurons. Brain Res Mol Brain Res 124:29-39.
14. Lee SM, Lee JW, Song YS, Hwang DY, Kim YK, Nam SY, Kim DJ, Yun YW, Yoon DY, and Hong JT (2005) Ryanodine receptor-mediated interference of neuronal cell differentiation by presenilin 2 mutation. J Neurosci Res 82:542-550.
15. Miyazaki J, Araki K, Yamato E, Ikegami H, Asano T, Shibasaki Y, Oka Y, and Yamamura K (1990) Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology 127:126-132.
16. Okamoto H and Takasawa S (2002) Recent advances in the Okamoto model: the CD38-cyclic ADP-ribose signal system and the regenerating gene protein (Reg)-Reg receptor system in beta-cells. Diabetes 51 (Suppl 3):S462-S473.
17. O'Mara SM, Rowan MJ, and Anwyl R (1995) Dantrolene inhibits long-term depression and depotentiation of synaptic transmission in the rat dentate gyrus. Neuroscience 68:621-624.
18. Parness J and Palnitkar SS (1995) Identification of dantrolene binding sites in porcine skeletal muscle sarcoplasmic reticulum. J Biol Chem 270:18465-18472.
19. Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, Miyazaki Y, Kohane I, Costello M, Saccone R, et al. (2003) Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 100:8466-8471.
20. Proks P, Reimann F, Green N, Gribble F, and Ashcroft F (2002) Sulfonylurea stimulation of insulin secretion. Diabetes 51 (Suppl 3):S368-S376.
21. Rorsman P and Renstrom E (2003) Insulin granule dynamics in pancreatic beta cells. Diabetologia 46:1029-1045.
22. Salas M and Caro JJ (2002) Are hypoglycaemia and other adverse effects similar among sulphonylureas? Adverse Drug React Toxicol Rev 21:205-217.
23. Sato Y, Nishikawa M, Shinkai H, and Sukegawa E (1991) Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D- phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals. Diabetes Res Clin Pract 12:53-59.
24. ATP channel-independent regulation of insulin secretion. J Biol Chem 275:9270-9277.
25. Shapiro ET, Van Cauter E, Tillil H, Given BD, Hirsch L, Beebe C, Rubenstein AH, and Polonsky KS (1989) Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 69:571-576.
26. Shigeto M, Katsura M, Matsuda M, Ohkuma S, and Kaku K (2006) First phase of glucose-stimulated insulin secretion from MIN6 cells does not always require extracellular calcium influx. J Pharmacol Sci 101:293-302.
27. Shiota C, Larsson O, Shelton KD, Shiota M, Efanov AM, Hoy M, Lindner J, Kooptiwut S, Juntti-Berggren L, Gromada J, et al. (2002) Sulfonylurea receptor type 1 knock-out mice have intact feeding-stimulated insulin secretion despite marked impairment in their response to glucose. J Biol Chem 277:37176-37183.
28. Straub SG and Sharp GW (2002) Glucose-stimulated signaling pathways in biphasic insulin secretion. Diabetes Metab Res Rev 18:451-463.
29. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837-853.
30. Zhang Z and Bourque CW (2006) Calcium permeability and flux through osmosensory transduction channels of isolated rat supraoptic nucleus neurons. Eur J Neurosci 23:1491-1500.